

## **Reimbursement Rate Updates for Procedure Code C9052 Effective for Dates of Service on or after July 1, 2019**

Information posted August 16, 2019

**Note:** *Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to eligible clients. Administrative procedures such as prior authorization, pre-certification, referrals, and claims/encounter data filing may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the client's specific MCO for details.*

Effective August 15, 2019, for dates of service on or after July 1, 2019, the reimbursement rate for procedure code C9052 Ultomiris (Ravulizumab-cwvz) will be \$229.26.

Affected claims with dates of service from July 1, 2019, through August 15, 2019, if any are identified, will be reprocessed. Providers are not required to appeal these claims unless they are denied for additional reasons after the claims reprocessing is complete.

For more information, call the TMHP Contact Center at 1-800-925-9126.